Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Mericon Industries Inc.
WARNING LETTER
•Mericon Industries Inc.•August 21, 2024

FDA WARNING_LETTER - Mericon Industries Inc. - August 21, 2024

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

Mericon Industries, located at 8819 N Pioneer Rd, Peoria, IL, was inspected by the FDA from August 12 to 21, 2024. The inspection revealed significant violations of the Federal Food, Drug, and Cosmetic Act, including issues related to unapproved new drugs, misbranded drugs, and adulterated dietary supplements.

Key violations include:

1. **Unapproved New Drugs**: Products such as Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules were marketed with claims that classify them as drugs under the Act. These products are not FDA-approved, making their interstate commerce introduction illegal.

2. **Misbranded Drugs**: The Florical capsules lack adequate directions for use, as they are intended for conditions requiring supervision by a licensed practitioner, thus failing to meet labeling requirements.

3. **Adulterated Dietary Supplements**: The facility failed to establish necessary product specifications and quality control procedures as per CGMP regulations (21 CFR Part 111). This includes inadequate identity testing and lack of written quality control procedures, leading to potential product misidentification and quality issues.

4. **Misbranded Dietary Supplements**: The product labels do not comply with dietary supplement labeling requirements, further misbranding the products.

The FDA requires Mericon Industries to take corrective actions, including establishing proper product specifications, implementing comprehensive quality control procedures, and ensuring compliance with labeling requirements. The company must provide evidence of these corrective actions to avoid further regulatory action.

Company
Mericon Industries Inc.
Inspection Date
August 21, 2024
Product Type
Drugs
Office
Human Foods Program
Person
  • George Tidmarsh (Director)
Open in Dashboard

ID · 56d455e4-cc7f-43f6-9e8a-ba685ab62f69

Violation Codes10
21 U.S.C. 34321 U.S.C. 343(q)(5)(F)21 U.S.C. 321(g)(1)(B)21 U.S.C. 352(f)(1)21 CFR 11121 CFR 111.10321 CFR 101.9(c)(8)(iv)21 U.S.C. 321(p)21 CFR 201.521 U.S.C. 342(g)(1)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.